Cargando…

Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer

Fluorometric quantification of biological molecules is a key feature used in many biosensing studies. Fluorescence resonance energy transfer (FRET) using highly fluorescent quantum dots offers highly sensitive detection of the in-proximity wide variety of analyst molecules. In this contribution, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Omer, Walaa E., Abdelbar, Mostafa F., El-Kemary, Nesma M., Fukata, Naoki, El-Kemary, Maged A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041374/
https://www.ncbi.nlm.nih.gov/pubmed/35498938
http://dx.doi.org/10.1039/d1ra05121k
_version_ 1784694532967759872
author Omer, Walaa E.
Abdelbar, Mostafa F.
El-Kemary, Nesma M.
Fukata, Naoki
El-Kemary, Maged A.
author_facet Omer, Walaa E.
Abdelbar, Mostafa F.
El-Kemary, Nesma M.
Fukata, Naoki
El-Kemary, Maged A.
author_sort Omer, Walaa E.
collection PubMed
description Fluorometric quantification of biological molecules is a key feature used in many biosensing studies. Fluorescence resonance energy transfer (FRET) using highly fluorescent quantum dots offers highly sensitive detection of the in-proximity wide variety of analyst molecules. In this contribution, we report the use of carbon quantum dots (CDs) for the ultrasensitive optical biosensing of cancer antigen 125 (CA-125) in the early malignant stage. This approach is based on monitoring the quenching of CDs luminescence at 535 nm by CA-125 after excitation at 425 nm and pH 10. The calibration of this method was performed in the concentration range of CA-125 from 0.01 to 129 U ml(−1) (R(2) = 0.99) with a detection limit of 0.66 U ml(−1), which matches remarkably with the standard chemiluminometric method in control and real patient samples. The sensing mechanism for cancer antigen 125 assessment was discussed on the basis of fluorescence quenching of CDs and time-resolved photoluminescence spectroscopy. The current method is easy, sensitive, cost-effective and provides a wide range of validity, which helps in overcoming the limitations of high cost and time consumption exhibited by many other traditional clinical assays for CA-125 quantification.
format Online
Article
Text
id pubmed-9041374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90413742022-04-28 Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer Omer, Walaa E. Abdelbar, Mostafa F. El-Kemary, Nesma M. Fukata, Naoki El-Kemary, Maged A. RSC Adv Chemistry Fluorometric quantification of biological molecules is a key feature used in many biosensing studies. Fluorescence resonance energy transfer (FRET) using highly fluorescent quantum dots offers highly sensitive detection of the in-proximity wide variety of analyst molecules. In this contribution, we report the use of carbon quantum dots (CDs) for the ultrasensitive optical biosensing of cancer antigen 125 (CA-125) in the early malignant stage. This approach is based on monitoring the quenching of CDs luminescence at 535 nm by CA-125 after excitation at 425 nm and pH 10. The calibration of this method was performed in the concentration range of CA-125 from 0.01 to 129 U ml(−1) (R(2) = 0.99) with a detection limit of 0.66 U ml(−1), which matches remarkably with the standard chemiluminometric method in control and real patient samples. The sensing mechanism for cancer antigen 125 assessment was discussed on the basis of fluorescence quenching of CDs and time-resolved photoluminescence spectroscopy. The current method is easy, sensitive, cost-effective and provides a wide range of validity, which helps in overcoming the limitations of high cost and time consumption exhibited by many other traditional clinical assays for CA-125 quantification. The Royal Society of Chemistry 2021-09-20 /pmc/articles/PMC9041374/ /pubmed/35498938 http://dx.doi.org/10.1039/d1ra05121k Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Omer, Walaa E.
Abdelbar, Mostafa F.
El-Kemary, Nesma M.
Fukata, Naoki
El-Kemary, Maged A.
Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
title Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
title_full Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
title_fullStr Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
title_full_unstemmed Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
title_short Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
title_sort cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041374/
https://www.ncbi.nlm.nih.gov/pubmed/35498938
http://dx.doi.org/10.1039/d1ra05121k
work_keys_str_mv AT omerwalaae cancerantigen125assessmentusingcarbonquantumdotsforopticalbiosensingfortheearlydiagnosisofovariancancer
AT abdelbarmostafaf cancerantigen125assessmentusingcarbonquantumdotsforopticalbiosensingfortheearlydiagnosisofovariancancer
AT elkemarynesmam cancerantigen125assessmentusingcarbonquantumdotsforopticalbiosensingfortheearlydiagnosisofovariancancer
AT fukatanaoki cancerantigen125assessmentusingcarbonquantumdotsforopticalbiosensingfortheearlydiagnosisofovariancancer
AT elkemarymageda cancerantigen125assessmentusingcarbonquantumdotsforopticalbiosensingfortheearlydiagnosisofovariancancer